Cystic renal cell carcinoma is a predominantly cystic lesion with a small solid component (25% or less). Renal cell carcinoma usually presents as a solid mass; however, in 10–22% of cases ...

Management of advanced renal cell carcinoma remains a persistent clinical challenge with high morbidity and mortality for a large proportion of patients. Until recently, available medical ...

Neoadjuvant therapy for high-risk renal cell carcinoma (RCC) may offer a survival advantage over adjuvant therapy, according to data presented at the 2024 annual meeting of the Society of Urologic ...

Figure 1: Characterization of the hybrid cell vaccine. The hybrid cell vaccination was well tolerated by all patients. There were no serious adverse effects or any clinical signs of autoimmune ...

The US Food and Drug Administration (FDA) has approved an investigational new drug (IND) application from Adicet Bio, ...

Phase 1 results support further evaluation of ALLO-316 in patients with CD70-positive clear cell renal cell carcinoma, according to researchers.

Jaime Merchan, MD, discusses the efficacy results observed in the LITESPARK-013 trial of belzutifan in patients with advanced clear cell renal cell carcinoma.